Harrow launches Vigamox in the U.S.

Harrow announced the completion of the transfer to Harrow of the New Drug Application (NDA) for Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. The U.S. commercial rights to Vigamox were purchased by Harrow in January of 2023, and Vigamox is the fourth FDA-approved ophthalmic product from that acquisition to have completed the NDA transfer process and become commercially available under the Harrow name.

“Having now completed the NDA transfer of Vigamox, we are excited to begin the implementation of the market access, marketing, inventory management, national sales detailing, and other brand‑leveraging strategies that we have developed during this transfer period,” said Mark L. Baum, Chief Executive Officer of Harrow in a press release. “With an exceptional record of safety and efficacy, Vigamox is a well-known, reliable, and trusted product by U.S. eyecare professionals, many of whom regard Vigamox as the preferred broad-spectrum topical antibiotic to treat patients for bacterial conjunctivitis (sometimes referred to as ‘pink eye’) as well as many other common bacterial-based infections.”

Read the full press release here.